BR112022002138A2 - Moduladores do receptor de estrogênio para tratamento de mutantes - Google Patents

Moduladores do receptor de estrogênio para tratamento de mutantes

Info

Publication number
BR112022002138A2
BR112022002138A2 BR112022002138A BR112022002138A BR112022002138A2 BR 112022002138 A2 BR112022002138 A2 BR 112022002138A2 BR 112022002138 A BR112022002138 A BR 112022002138A BR 112022002138 A BR112022002138 A BR 112022002138A BR 112022002138 A2 BR112022002138 A2 BR 112022002138A2
Authority
BR
Brazil
Prior art keywords
estrogen receptor
mutants
treatment
receptor modulators
breast cancer
Prior art date
Application number
BR112022002138A
Other languages
English (en)
Inventor
Abdi Samatar Ahmed
Fernando Donate
Jiali Li
Jianhui Ma
Duane Bunker Kevin
Qinhua Huang Peter
Gajanan Hegde Sayee
Original Assignee
Recurium Ip Holdings Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Recurium Ip Holdings Llc filed Critical Recurium Ip Holdings Llc
Publication of BR112022002138A2 publication Critical patent/BR112022002138A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)

Abstract

moduladores do receptor de estrogênio para tratamento de mutantes. a presente invenção se refere a usos e métodos que incluem uma quantidade eficaz de composto a (isto é, ácido (e)-3-(4-((1r, 3r)-2-(biciclo[1.1.1]pen-tan-1-il)-3-metil-2,3,4,9-tetra-hidro-1h-pirido[3,4-b]indol-1-il)-3,5-difluorofenil) acrílico), ou um sal farmaceuticamente aceitável do mesmo, que são aqui descritos para tratar câncer de mama em um indivíduo que esteja precisando do mesmo, sendo que o câncer de mama tem ao menos uma mutação pontual dentro do receptor de estrogênio 1 (esr1) que codifica o receptor de estrogênio alfa (rea), como y537s ou l536p.
BR112022002138A 2019-08-06 2020-08-04 Moduladores do receptor de estrogênio para tratamento de mutantes BR112022002138A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962883395P 2019-08-06 2019-08-06
US202063009746P 2020-04-14 2020-04-14
PCT/US2020/044884 WO2021026153A1 (en) 2019-08-06 2020-08-04 Estrogen receptor modulators for treating mutants

Publications (1)

Publication Number Publication Date
BR112022002138A2 true BR112022002138A2 (pt) 2022-04-19

Family

ID=74499460

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022002138A BR112022002138A2 (pt) 2019-08-06 2020-08-04 Moduladores do receptor de estrogênio para tratamento de mutantes

Country Status (12)

Country Link
US (2) US11278532B2 (pt)
EP (1) EP3993787A4 (pt)
JP (1) JP2022543832A (pt)
KR (1) KR20220044528A (pt)
CN (1) CN114269342A (pt)
AU (1) AU2020326691A1 (pt)
BR (1) BR112022002138A2 (pt)
CA (1) CA3148221A1 (pt)
IL (1) IL290280A (pt)
MX (1) MX2022001149A (pt)
TW (1) TW202120084A (pt)
WO (1) WO2021026153A1 (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024502270A (ja) 2020-12-23 2024-01-18 リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー エストロゲン受容体調節薬

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CZ264996A3 (cs) 1994-03-11 1998-01-14 Eli Lilly And Company Použití sloučenin, které jsou aktivní na 5HT2B receptor
GB9604996D0 (en) 1996-03-08 1996-05-08 Black James Foundation Benzodiazonine derivatives
EP1113007A1 (en) 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
DE60216952T2 (de) 2001-10-19 2007-07-05 Transtech Pharma Inc. Beta-carbolin-derivate als ptp-inhibitoren
US8076352B2 (en) 2004-03-15 2011-12-13 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
US20080103164A1 (en) 2004-08-02 2008-05-01 Kristjan Gudmundsson Useful compounds for hpv infection
WO2007002051A1 (en) 2005-06-22 2007-01-04 Smithkline Beecham Corporation Carboline derivatives and their use as inhibitors of flaviviridae infections
EP2037905B1 (en) 2006-06-23 2013-05-01 Radius Health, Inc. Treatment of vasomotor symptoms with selective estrogen receptor modulators
CA2683444A1 (en) 2007-04-13 2008-10-23 Ptc Therapeutics, Inc. Administration of carboline derivatives useful in the treatment of cancer and other diseases
DE102007028515A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
TW201028414A (en) 2009-01-16 2010-08-01 Merck Sharp & Dohme Oxadiazole beta carboline derivatives as antidiabetic compounds
US20120135089A1 (en) 2009-03-17 2012-05-31 Stockwell Brent R E3 ligase inhibitors
CA2785790A1 (en) 2010-01-15 2011-07-21 Merck Sharp & Dohme Corp. Oxadiazole beta carboline derivatives as antidiabetic compounds
WO2011103487A1 (en) 2010-02-18 2011-08-25 Medivation Technologies, Inc. Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use
EP2580210B1 (en) 2010-06-10 2017-03-01 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
CN102432608B (zh) 2011-11-01 2013-04-17 浙江大学 手性螺环磷酸催化合成光学活性四氢-β-咔啉衍生物的方法
US9187460B2 (en) 2011-12-14 2015-11-17 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
DK2797921T3 (en) 2011-12-31 2017-10-02 Beigene Ltd FUSED TETRA- OR PENTA-CYCLIC DIHYDRODIAZEPINOCARBAZOLONES AS PARB INHIBITORS
WO2013142266A1 (en) 2012-03-20 2013-09-26 Seragon Pharmaceuticals, Inc. Estrogen receptor modulators and uses thereof
AU2013203600C1 (en) 2012-07-13 2016-11-24 University Of Tennessee Research Foundation A method of treating androgen receptor (AR)-positive breast cancers with selective androgen receptor modulator (SARMS)
AU2014219283C1 (en) 2013-02-19 2016-10-27 Novartis Ag Benzothiophene derivatives and compositions thereof as selective estrogen receptor degraders
JP2016517420A (ja) 2013-03-14 2016-06-16 セラゴン ファーマシューティカルズ， インク． 多環式エストロゲン受容体モジュレーター及びその使用
PT3004090T (pt) 2013-05-28 2017-12-22 Astrazeneca Ab Compostos químicos
WO2015082990A1 (en) 2013-12-06 2015-06-11 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator for the treatment of locally advanced or metastatic estrogen receptor positive breast cancer
CN104693211A (zh) 2013-12-10 2015-06-10 南京明德新药研发股份有限公司 作为抗病毒剂的咪唑衍生物及其制药用途
US9695166B2 (en) 2014-05-05 2017-07-04 Global Blood Therapeutics, Inc. Pyrazolopyridine pyrazolopyrimidine and related compounds
EP3143007B1 (en) 2014-05-16 2018-07-11 Idorsia Pharmaceuticals Ltd Antibacterial quinazoline-4(3h)-one derivatives
CN106536520B (zh) 2014-06-27 2020-08-14 诺格拉制药有限公司 芳基受体调制剂及其制备和使用方法
AU2015330490B2 (en) 2014-10-09 2018-08-09 Guangdong Raynovent Biotech Co., Ltd. Hydroxyl purine compounds and applications thereof
CN117865872A (zh) 2014-12-18 2024-04-12 豪夫迈·罗氏有限公司 四氢-吡啶并[3,4-b]吲哚雌激素受体调节剂及其用途
US10654809B2 (en) 2016-06-10 2020-05-19 University Of Tennessee Research Foundation Selective androgen receptor degrader (SARD) ligands and methods of use thereof
CA2983403A1 (en) 2015-04-21 2016-10-27 Gtx, Inc. Selective androgen receptor degrader (sard) ligands and methods of use thereof
KR20180012853A (ko) 2015-06-16 2018-02-06 지앙수 헨그루이 메디슨 컴퍼니 리미티드 피페리딘 유도체 및 이의 제조 방법 및 약학적 용도
US10519148B2 (en) 2015-11-12 2019-12-31 Zhejiang Hisun Pharmaceutical Co., Ltd. Acrylic acid derivative, preparation method and use in medicine thereof
JP6905539B2 (ja) 2016-02-05 2021-07-21 インベンティスバイオ リミテッド ライアビリティ カンパニー 選択的エストロゲン受容体分解剤およびその使用
RU2738646C2 (ru) * 2016-04-01 2020-12-15 РЕКЬЮРИУМ АйПи ХОЛДИНГС, ЛЛС Модуляторы эстрогеновых рецепторов
JP6956747B2 (ja) 2016-06-10 2021-11-02 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体分解剤（ｓａｒｄ）リガンドおよびその使用方法
CA3027563A1 (en) * 2016-06-22 2017-12-28 Radius Health, Inc. Ar+ breast cancer treatment methods
WO2018001232A1 (zh) 2016-06-29 2018-01-04 浙江海正药业股份有限公司 丙烯酸类衍生物及其制备方法和其在医药上的用途
CN110139674B (zh) 2016-10-05 2023-05-16 豪夫迈·罗氏有限公司 制备抗体药物缀合物的方法
WO2018130124A1 (zh) 2017-01-11 2018-07-19 南京圣和药业股份有限公司 作为选择性雌激素受体下调剂的三环类化合物及其应用

Also Published As

Publication number Publication date
US20210038573A1 (en) 2021-02-11
MX2022001149A (es) 2022-04-06
KR20220044528A (ko) 2022-04-08
IL290280A (en) 2022-04-01
EP3993787A1 (en) 2022-05-11
EP3993787A4 (en) 2023-07-12
CN114269342A (zh) 2022-04-01
US20220125769A1 (en) 2022-04-28
US11278532B2 (en) 2022-03-22
WO2021026153A1 (en) 2021-02-11
JP2022543832A (ja) 2022-10-14
AU2020326691A1 (en) 2022-03-03
CA3148221A1 (en) 2021-02-11
TW202120084A (zh) 2021-06-01

Similar Documents

Publication Publication Date Title
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
BR112014032346A2 (pt) métodos para tratamento de malignidades resistentes ao inibidor de tirosina-quinase em pacientes com polimorfismos genéticos ou desregulações de ahi1 mutações empregando dianidrogalactitol, diacetildianidrogalactitol, dibromodulcitol, ou análogos ou derivados destes
MX2022010082A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
MX2021013830A (es) Inhibidores de ezh2 para tratar linfomas.
MX2021005561A (es) Rad1901 para usarse en el tratamiento de cancer en sujetos con cancer positivo a receptor de estrogeno alfa resistente a farmaco.
MX2016014308A (es) Compuestos y composiciones como agonistas del receptor tipo toll 7.
MX2022016434A (es) Inhibidores de glicolato oxidasa para el tratamiento de enfermedades.
MX2017013142A (es) Terapia combinada para tratar cáncer.
NZ724792A (en) Compounds and compositions as toll-like receptor 7 agonists
WO2014194254A8 (en) Treatment of cancers using pi3 kinase isoform modulators
WO2016060564A8 (en) Body sculpting
SA519410320B1 (ar) مركبات فينيل -2-هيدروكسي-أسيتيل أمينو -2-ميثيل-فينيل
MX2019010149A (es) Inhibicion del smarca2 para el tratamiento del cancer.
BR112019011199A2 (pt) método para tratar um indivíduo que tem um câncer de próstata e kits
CR20220207A (es) Compuestos terapéuticos y métodos de uso
AR092899A1 (es) Uso de masitinib para el tratamiento del cancer en subpoblaciones de pacientes identificados que utilizan factores de prediccion
BR112022000992A2 (pt) Regimes de tratamento de dexmedetomidina não sedantes
WO2016172494A3 (en) Combination of immunotherapy with local chemotherapy for the treatment of malignancies
PH12015502260A1 (en) C. novyi for the treatment of solid tumors in humans
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
MX2019012176A (es) Metodos de combinacion de chk1(sra737)/parpi para inhibir el crecimiento tumoral.
BR112021006318A2 (pt) terapia de combinação para o tratamento de câncer
PH12020551495A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
MX2022004524A (es) Tratamiento génico para la enfermedad de alzheimer.
BR112022002138A2 (pt) Moduladores do receptor de estrogênio para tratamento de mutantes

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]